Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

May’s #BeanoftheMonth is dedicated to our #OfficeDog & all other pups keeping us sane & healthy during the #pandemic. This @nytopinion piece by a cognitive scientist who researches dogs illustrates how our dogs help us cope with #isolation in a crisis: https://t.co/OgKyr0KH5D

Big #Congrats to our client, @Themis_Bio on its #acquisition by MSD. MSD will apply its #VaccineDevelopment capabilities to the SARS-CoV-2 vaccine program originated by @institutpasteur & Themis. #COVID19

Big #Congrats to our client, @Themis_Bio on its #acquisition by MSD. MSD will apply its #VaccineDevelopment capabilities to the SARS-CoV-2 vaccine program originated by @institutpasteur & Themis. #COVID19
Themis Bio@Themis_Bio

Today we are excited to announce our #acquisition by MSD.

Amidst pandemic science works across borders but governments revert back to national protectiveness-a recent example from Germany is tightening oversight on foreign investments. This will hurt GER #biotech as international investments r critical 4 success in our industry #COVID19

ZEIT ONLINE@zeitonline

Die #Bundesregierung verschärft die #Außenwirtschaftsverordnung. Damit sollen Unternehmen im Gesundheitssektor besser vor Übernahmen aus dem Nicht-EU-Ausland geschützt werden. Die Wirtschaft lehnt das ab. https://t.co/ghG4Bpxqsj

Load More...